BioSpace News Archive

Sepha, specialist in leak test solutions for the pharmaceutical packaging industry, will be introducing its newly patented 3D Leak Detection technology for pharmaceutical blister packs via two live online webinars on the 2nd and 3rd December 2020.

Titan Pharmaceuticals, Inc. announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company’s common stock, which will be effective at 5:00 p.m. Eastern Time on Monday, November 30, 2020.

Also Includes a New Donation of Personal Protective Equipment (PPE) Directed Toward Health Workers in Underserved Communities Worldwide

Exactech, a developer and producer of innovative implants, instrumentation and the Active Intelligence® platform of technologies for joint replacement surgery, announced today the launch of Predict+™, a data-driven, clinical decision support tool that uses machine learning to predict individual patient outcomes after shoulder replacement surgery to assist surgeon decision making.

The 2020 American Geophysical Union Fall Meeting will include a feature presentation from Battelle Chief Scientist Mike Kuhlman, National Ecological Observatory Network Chief Scientist and Observatory Director Paula Mabee, Battelle Senior Project Manager Tom Hutchings, and Systems Integration Specialist Nicolas Romano.

Counseling by a physical therapist has the potential to improve physical activity in people with inflammatory arthritis, according to an Arthritis Research Canada study.

Publication in Nature Communications demonstrates robust neutralizing antibodies and T cell responses against SARS-CoV-2

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Robert M. Davis, chief financial officer and executive vice president, Merck Global Services, is scheduled to participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Dec. 2, 2020, at 9:40 a.m. EST. Investors, analysts, members of the media and the general public are invited to listen to

Lannett Company, Inc. announced that the company used a portion of its existing cash on hand to pay off, in full, the remaining $42 million outstanding balance of its Term A Loans.

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the European Commission has granted orphan designation for PR006 for the treatment of frontotemporal dementia (FTD). PR006 is an investigational AAV9 gene therapy delivering the GRN gene and is being developed as a potential therapy for patients with